SLNO vs. INMD, BLFS, CNMD, LRMR, RYTM, EDAP, FONR, RMTI, LIVN, and ITGR
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include InMode (INMD), BioLife Solutions (BLFS), CONMED (CNMD), Larimar Therapeutics (LRMR), Rhythm Pharmaceuticals (RYTM), Edap Tms (EDAP), FONAR (FONR), Rockwell Medical (RMTI), LivaNova (LIVN), and Integer (ITGR). These companies are all part of the "medical" sector.
Soleno Therapeutics (NASDAQ:SLNO) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.
Soleno Therapeutics currently has a consensus price target of $60.33, indicating a potential upside of 29.89%. InMode has a consensus price target of $32.80, indicating a potential upside of 77.68%. Given InMode's higher possible upside, analysts plainly believe InMode is more favorable than Soleno Therapeutics.
InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by insiders. Comparatively, 6.9% of InMode shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
InMode has a net margin of 38.84% compared to Soleno Therapeutics' net margin of 0.00%. InMode's return on equity of 26.15% beat Soleno Therapeutics' return on equity.
Soleno Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.
Soleno Therapeutics received 143 more outperform votes than InMode when rated by MarketBeat users. However, 75.12% of users gave InMode an outperform vote while only 71.43% of users gave Soleno Therapeutics an outperform vote.
In the previous week, Soleno Therapeutics had 7 more articles in the media than InMode. MarketBeat recorded 13 mentions for Soleno Therapeutics and 6 mentions for InMode. InMode's average media sentiment score of 1.00 beat Soleno Therapeutics' score of 0.30 indicating that InMode is being referred to more favorably in the news media.
Summary
InMode beats Soleno Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
